Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL696233 | 0.88 | MAPT (0.51) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL17813139 | 0.85 | MAPT (0.48) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL2482873 | 0.83 | HPGD (0.56) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL8084718 | 0.81 | SMN1; SMN2 (0.46) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL11477630 | 0.80 | MAPT (0.42) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL28493144 | 0.80 | AR (0.55) | MAPTSMN1; SMN2 | |
| SCHEMBL11477620 | 0.79 | MAPT (0.42) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL695457 | 0.76 | FKBP1A (0.48) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL17813026 | 0.76 | MAPT (0.42) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL31480971 | 0.75 | ALDH1A1 (0.48) | MAPTALDH1A1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362221-A1 | INHIBITORS OF KIDNEY-TYPE GLUTAMINASE, GLS-1 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362221-A1 | INHIBITORS OF KIDNEY-TYPE GLUTAMINASE, GLS-1 | GLS, GLS2, GLUL | MAPT 4699/4885ALDH1A1 392/4885MEN1 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.